Based on the observed reduction in plasma neurofilament light chain (NfL) levels in patients receiving treatment, in 2023, tofersen received the FDA’s accelerated approval for the treatment of ALS patients with SOD1 gene mutations. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.